Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zile

Showing results (881-890 of 1,060) with videos related to

Pageof 106
Sort By:
Circulation. Heart Failure|March 16, 2019
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation StatusSøren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
Journal of the American Veterinary Medical Association|July 26, 2023
Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trialJoanna L Kaplan, Victor N Rivas, Ashley L Walker, et al.
JACC. Heart Failure|July 5, 2023
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/ValsartanJames P Curtain, Carly Adamson, Kieran F Docherty, et al.
Circulation. Heart Failure|March 21, 2023
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF TrialJawad H Butt, Wasyla Ibrahim, Pooja Dewan, et al.
European Journal of Heart Failure|April 8, 2024
Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HFShingo Matsumoto, Mingming Yang, Li Shen, et al.
International Journal of Cardiology|April 30, 2018
Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery diseaseMarcel Halbach, William T Abraham, Christian Butter, et al.
Journal of the American College of Cardiology|February 7, 2024
Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection FractionJoAnn Lindenfeld, Maria Rosa Costanzo, Michael R Zile, et al.
Journal of Hypertension|July 30, 2011
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertensionAmil M Shah, Carolyn S P Lam, Susan Cheng, et al.
Seminars in Thoracic and Cardiovascular Surgery|January 4, 2017
Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection FractionFred A Weaver, William T Abraham, William C Little, et al.
Circulation. Heart Failure|October 26, 2018
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart FailureJames L Januzzi, Milton Packer, Brian Claggett, et al.
Pageof 106

Showing results (881-890 of 1,060) with videos related to

Sort By:
Pageof 106
Circulation. Heart Failure|March 16, 2019
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation StatusSøren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
Journal of the American Veterinary Medical Association|July 26, 2023
Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trialJoanna L Kaplan, Victor N Rivas, Ashley L Walker, et al.
JACC. Heart Failure|July 5, 2023
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/ValsartanJames P Curtain, Carly Adamson, Kieran F Docherty, et al.
Circulation. Heart Failure|March 21, 2023
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF TrialJawad H Butt, Wasyla Ibrahim, Pooja Dewan, et al.
European Journal of Heart Failure|April 8, 2024
Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HFShingo Matsumoto, Mingming Yang, Li Shen, et al.
International Journal of Cardiology|April 30, 2018
Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery diseaseMarcel Halbach, William T Abraham, Christian Butter, et al.
Journal of the American College of Cardiology|February 7, 2024
Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection FractionJoAnn Lindenfeld, Maria Rosa Costanzo, Michael R Zile, et al.
Journal of Hypertension|July 30, 2011
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertensionAmil M Shah, Carolyn S P Lam, Susan Cheng, et al.
Seminars in Thoracic and Cardiovascular Surgery|January 4, 2017
Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection FractionFred A Weaver, William T Abraham, William C Little, et al.
Circulation. Heart Failure|October 26, 2018
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart FailureJames L Januzzi, Milton Packer, Brian Claggett, et al.
Pageof 106